Breakdown from Distribution Zone – Bearish Continuation Likely

The chart clearly reflects a long-term topping structure followed by sustained weakness, with price now approaching a critical support breakdown zone near ₹800. From an Elliott Wave perspective, the stock appears to have completed a full 5-wave uptrend, followed by a prolonged ABC corrective phase. The recent price action suggests that Wave B (temporary recovery) has already played out, and the stock is now entering Wave C, which typically mirrors the intensity of Wave A and often leads to deeper corrections. On the momentum side, the structure indicates a bearish MACD alignment, with repeated lower highs in price likely accompanied by weakening momentum. The inability to sustain rallies and continuous rejection near moving averages signals that sellers are consistently active on every bounce. Looking at AVWAP, if anchored from the major top (around ₹1,250+ levels), price has consistently traded below AVWAP, confirming a strong bearish regime. Every pullback towards ₹900–₹950 has faced rejection, making this zone a strong supply area. The current breakdown attempt below ₹800 further strengthens the bearish continuation setup. Additionally, the price is trading below key moving averages (short, medium, and long term), all of which are now sloping downward, reinforcing the ongoing downtrend. From a fundamental standpoint: The company remains a well-established player in the pharma space However, growth visibility has been relatively moderate in recent quarters Margins and earnings consistency have shown some pressure compared to peak performance phases